Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Arranging Arrakis' syndicate

How Arrakis is plotting a path forward with its RNA-targeting small molecules

As it raised a $75 million series B round that will help its early research coalesce into a preclinical pipeline, Arrakis sought an investor syndicate that would build its expertise as it seeks to become an integrated, publicly traded biopharma.

Arrakis Therapeutics Inc. has begun its first four programs developing RNA-targeting small molecules -- "rSMs" -- including three oncology programs and one cardiovascular project. But

Read the full 648 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE